Phone: 1-617-401-8149
Fax: 1-617-606-5019
Email: message@sydlabs.com
Or leave a message with a formal purchase
order (PO) Or credit card.
Catalog No. | Product Name | Size | List Price (US$) | Quantity |
---|
Price/availability/specifications subject to change without notice. Unless otherwise indicated, our catalog and customized products are for research use only and not intended for human or animal diagnostic or therapeutic use.
Phone: 1-617-401-8149
Fax: 1-617-606-5019
Email: message@sydlabs.com
Or leave a message with a formal purchase
order (PO) Or credit card.
Background Information:
Serabelisib (MLN1117, TAK-117, INK1117) is an orally bioavailable, PI3K p110α- isoform specific inhibitor with an in vitro IC50 of 15 nM, highly selective against other isoforms (p110β, p110γ and p110δ) and mTOR (no significant inhibitions at 1 μM concentration). It displayed significant efficacy in several PI3Kα mutant-specific preclinical mouse xenograft tumor models, and blocked signaling to Akt and inhibited growth of cancer cells harboring wild-type or mutated p110α. It is currently under clinical evaluation.
APIM050240: SERABELISIB (MLN1117, INK1117, TAK-117)
CAS No.: 1268454-23-4.
Molecular Formula: C19H17N5O3.
Molecular Weight: 363.4 (refer to Certificate of Analysis, batch-specific).
Purity: 99.5% by HPLC.
QC: HPLC-MS. 1H-NMR, and Elemental Analysis Report.
Solubility: Refer to Certificate of Analysis.
Storage: Refer to Certificate of Analysis.
Copyright © 2009-2022 sydlabs.com. All rights reserved.
Use of this website means that you have read, understood, and accepted the Syd Labs Privacy Policy and Terms & Conditions.